ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2026
Cycle thresholds and discordant 2-step testing for Clostridioides Difficile: Comparison of clinical characteristics and outcomes among discordant and true positive results.
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine if Toxin B polymerase chain reaction (PCR) cycle threshold (Ct) can help identify which patients with discordant clostridioides difficile (CD) PCR and enzyme immunoassay testing (EIA) may benefit from treatment. Design: Retrospective case series. Setting: Multi-hospital tertiary Academic system. Patients: All admitted adult patients with positive CD PCR over a 6 month period (n = 214). Patients with positive Stool PCR for other pathogens were excluded. Methods: Chart review of all eligible patients. CD testing results, patient demographics, underlying comorbidities, symptoms prompting testing, risk factors for CD, markers of severe disease, treatment regimens, and clinical outcomes including: 30-day all-cause mortality and re-admission, and 60-day CDI repeat testing and treatment were collected. Results: Significant association between mortality and lower Ct values among discordant patients who were not treated compared to those who were (P = 0.042). The association between Ct values and 30-day readmission was significantly stronger among untreated patients compared to those who were treated (P = .034). A similar trend was observed among non-severe, untreated patients with low Ct values and subsequent CDI treatment within 60 days (CT < 26, 49% vs. CT > 26, 18%, P = .063). Conclusions: Untreated patients with lower cycle thresholds had worse clinical outcomes compared to untreated patients with higher Ct, regardless of disease severity. A lower PCR Ct can support treatment in patients with clinical disease, positive PCR and negative toxin EIA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.